CytoMed Therapeutics Limited (GDTC) Stock Analysis & Investment Frameworks

CytoMed Therapeutics Limited (GDTC) stock analysis on Invetso. Review CytoMed Therapeutics Limited’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

CytoMed Therapeutics Limited Company Overview

CytoMed Therapeutics Limited Key Financial Metrics

About CytoMed Therapeutics Limited

CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.

CytoMed Therapeutics Limited Investment Frameworks

Invetso analyzes CytoMed Therapeutics Limited (GDTC) across the following frameworks:

Explore More GDTC Research